Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells

FEMS Immunology and Medical Microbiology

Volumn 61, Issue 3, 2011, Pages 332-339

  Farfán, Mauricio J ^a,b   Toro, Cecilia S ^a   Barry, Eileen M ^b   Nataro, James P ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

IL 8 secretion; ShET 2; Shigella flexneri; Type III secretion system

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL TOXIN; BETA LACTAMASE TEM 1; ENTEROTOXIN; HYBRID PROTEIN; INTERLEUKIN 8; OUTER SURFACE PROTEIN C1; SHIGELLA ENTEROTOXIN 2; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL GENE; BACTERIAL SECRETION SYSTEM; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CELL INVASION; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DELETION MUTANT; EPITHELIUM CELL; EXPERIMENTAL GUINEA PIG; EXTRACELLULAR SPACE; FUSION GENE; GENE DELETION; INFLAMMATION; KERATOCONJUNCTIVITIS; MONOLAYER CULTURE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PLAQUE FORMING CELL; PLASMID; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SHIGELLA FLEXNERI; SHIGELLOSIS; STRAIN DIFFERENCE; TYPE III BACTERIAL SECRETION SYSTEM; WILD TYPE;

ANIMALS; CELL LINE; ENTEROTOXINS; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-8; PROTEIN TRANSPORT; SHIGELLA FLEXNERI;

EID: 79952607599     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00778.x     Document Type: Article

References (38)

1. Arbibe L, Kim DW, Batsche E et al. (2007) An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 8: 47-56.
2. Ashida H, Toyotome T, Nagai T & Sasakawa C (2007) Shigella chromosomal IpaH proteins are secreted via the type III secretion system and act as effectors. Mol Microbiol 63: 680-693.
3. Bahrani FK, Sansonetti PJ & Parsot C (1997) Secretion of Ipa proteins by Shigella flexneri: inducer molecules and kinetics of activation. Infect Immun 65: 4005-4010.
4. Buchrieser C, Glaser P, Rusniok C et al. (2000) The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol Microbiol 38: 760-771.
5. Cersini A, Martino MC, Martini I, Rossi G & Bernardini ML (2003) Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants. Infect Immun 71: 7002-7013.
6. Charpentier X & Oswald E (2004) Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol 186: 5486-5495.
7. Datsenko KA & Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. P Natl Acad Sci USA 97: 6640-6645.
8. Fasano A, Noriega FR, Maneval DR Jr, Chanasongcram S, Russell R, Guandalini S & Levine MM (1995) Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 95: 2853-2861.
9. Harrington SM, Strauman MC, Abe CM & Nataro JP (2005) Aggregative adherence fimbriae contribute to the inflammatory response of epithelial cells infected with enteroaggregative Escherichia coli. Cell Microbiol 7: 1565-1578.
10. Kane CD, Schuch R, Day WA Jr & Maurelli AT (2002) MxiE regulates intracellular expression of factors secreted by the Shigella flexneri 2a type III secretion system. J Bacteriol 184: 4409-4419.
11. Keusch GT, Jacewicz M & Donohue-Rolfe A (1986) Pathogenesis of Shigella diarrhea: evidence for an N-linked glycoprotein Shigella toxin receptor and receptor modulation by beta-galactosidase. J Infect Dis 153: 238-248.
12. Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ & Parsot C (2005) The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. P Natl Acad Sci USA 102: 14046-14051.
13. Kotloff KL, Winickoff JP, Ivanoff B et al. (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. B World Health Organ 77: 651-666.
14. Kotloff KL, Noriega FR, Samandari T et al. (2000) Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68: 1034-1039.
15. Kotloff KL, Pasetti MF, Barry EM et al. (2004) Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190: 1745-1754.
16. Kotloff KL, Simon JK, Pasetti MF et al. (2007) Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 3: 268-275.
17. Le Gall T, Mavris M, Martino MC, Bernardini ML, Denamur E & Parsot C (2005) Analysis of virulence plasmid gene expression defines three classes of effectors in the type III secretion system of Shigella flexneri. Microbiology 151: 951-962.
18. Levine MM, Kotloff KL, Barry EM, Pasetti MF & Sztein MB (2007) Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5: 540-553.
19. Mavris M, Page AL, Tournebize R, Demers B, Sansonetti P & Parsot C (2002) Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus. Mol Microbiol 43: 1543-1553.
20. Menard R, Sansonetti P & Parsot C (1994) The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD. EMBO J 13: 5293-5302.
21. Mota LJ & Cornelis GR (2005) The bacterial injection kit: type III secretion systems. Ann Med 37: 234-249.
22. Nataro JP, Seriwatana J, Fasano A et al. (1995) Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 63: 4721-4728.
23. Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY & Levine MM (1996) Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun 64: 3055-3061.
24. Oaks EV, Wingfield ME & Formal SB (1985) Plaque formation by virulent Shigella flexneri. Infect Immun 48: 124-129.
25. Okuda J, Toyotome T, Kataoka N et al. (2005) Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses. Biochem Bioph Res Co 333: 531-539.
26. Parsot C (2005) Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 252: 11-18.
27. Parsot C (2009) Shigella type III secretion effectors: how, where, when, for what purposes? Curr Opin Microbiol 12: 110-116.
28. Parsot C, Ageron E, Penno C et al. (2005) A secreted anti-activator, OspD1, and its chaperone, Spa15, are involved in the control of transcription by the type III secretion apparatus activity in Shigella flexneri. Mol Microbiol 56: 1627-1635.
29. Phalipon A, Mulard LA & Sansonetti PJ (2008) Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? Microbes Infect 10: 1057-1062.
30. Philpott DJ, Yamaoka S, Israel A & Sansonetti PJ (2000) Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 165: 903-914.
31. Ranallo RT, Barnoy S, Thakkar S, Urick T & Venkatesan MM (2006) Developing live Shigella vaccines using lambda Red recombineering. FEMS Immunol Med Mic 47: 462-469.
32. Schroeder GN & Hilbi H (2008) Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 21: 134-156.
33. Singer M & Sansonetti PJ (2004) IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 173: 4197-4206.
34. Slagowski NL, Kramer RW, Morrison MF, LaBaer J & Lesser CF (2008) A functional genomic yeast screen to identify pathogenic bacterial proteins. PLoS Pathog 4: e9.
35. Vargas M, Gascon J, Jimenez De Anta MT & Vila J (1999) Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with traveler's diarrhea. J Clin Microbiol 37: 3608-3611.
36. Watarai M, Tobe T, Yoshikawa M & Sasakawa C (1995) Contact of Shigella with host cells triggers release of Ipa invasins and is an essential function of invasiveness. EMBO J 14: 2461-2470.
37. Zurawski DV, Mitsuhata C, Mumy KL, McCormick BA & Maurelli AT (2006) OspF and OspC1 are Shigella flexneri type III secretion system effectors that are required for postinvasion aspects of virulence. Infect Immun 74: 5964-5976.
38. Zurawski DV, Mumy KL, Faherty CS, McCormick BA & Maurelli AT (2009) Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein. Mol Microbiol 71: 350-368.